In patients without a gallbladder, this delayed transit can intensify bile-related discomfort because bile continuously bathing the intestinal lining meets slower-moving, partially digested fats

Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended References Simmonds M, Llewellyn A, Owen CG, Woolacott N

Estos efectos pleiotrpicos explican por qu la GLP-1 se ha convertido en un objetivo teraputico importante para el tratamiento de la diabetes tipo 2 y, ms recientemente, para el manejo del sobrepeso y la obesidad
PubMed Central, Li, Rui, et al
Notably, Illinois Medicaid does not cover Ozempic solely for weight loss or obesity, even though the state recently expanded such coverage for state employees